YTYing Tian

Ying Tian

*This is an algorithmically generated author record based on publicly available information.

Ying Tian has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bortezomib-based Regimens Improve Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study

    by Huijuan Wang, Huixing Zhou, Zhiyao Zhang, Chuanying Geng, Wenming Chen

    Objective: The management experience for plasma cell leukemia (PCL) is still limited by PCL's rare incidence and aggressive course. The goal of this study was to further identify the efficacy of bortezomibcontaining regimens for PCL in Chinese patients. Materials and Methods: In this study, 56 consecutive PCL patients [14 primary PCL (pPCL) and 42 secondary PCL (sPCL) cases] were retrospectively enrolled and 42/56 patients received bortezomibbased regimens (BBRs), including 10/14 pPCL and 32/42 sPCL patients. The patients' survival data, clinical information, and safety data were collected and analyzed. Results: In pPCL and sPCL patients, the overall response rate in the bortezomib group was 90.0 0 10 and 25.0%, respectively. The median progression-free survival from PCL diagnosis for pPCL and sPCL was 8.3 months vs. 2.9 months (p=0.043) and median overall survival (OS) from PCL diagnosis was 23.3 months vs. 4.0 months. The OS for patients receiving BBRs was significantly longer for both pPCL (8.3 vs. 1.2 months, p=0.002) and sPCL (4.3 vs. 1.1 months, p= VGPR) (p=0.035, HR=0.19, 95% CI=0.040.74) were independent predictors of OS for sPCL patients. For pPCL patients, BBR predicted OS (p=0.029, HR=0.056, 95% CI=0.004-0.745) instead of >= VGPR (p=0.272, HR=3.365, 95 0 /o CI=0.38-29.303). Conclusion: It was found that BBRs could significantly improve OS for both pPCL and sPCL patients.


  • Open Access

    Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma

    by Ying Tian, Yue Zhang, Wan-Qiu Zhu, Xiao-Lei Chen, He-Bing Zhou, Wen-Ming Chen

    The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.


  • A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment

    by Aijun Liu, Guangzhong Yang, Chuanying Geng, Huijuan Wang, Lihong Li, Yanchen Li, Yin Wu, Ying Tian, Yun Leng, Guorong Wang, et al.

    To analyze the effects of bortezomib on the prognosis of the newly diagnosed multiple myeloma patients with renal impairment, we assessed the outcomes of 134 multiple myeloma patients with renal impairment (serum creatinine ≥178 μmol/l) who were treated at Beijing Chaoyang Hospital. The patients were divided into two groups: bortezomib (n = 83) and nonbortezomib (n = 51). The overall response rate of the bortezomib group was higher than that of the nonbortezomib group. There was no significant difference in the time to restore renal function, but the complete renal response ratio was significantly higher in the bortezomib group. The 2-year overall survival (OS) rate of the bortezomib group was significantly greater than the nonbortezomib group, as was the 3-year OS rate. Kaplan-Meier analysis revealed significantly better survival for the bortezomib group. The main side effects in the bortezomib group were thrombocytopenia, peripheral neuropathy, infection, and herpes zoster, and there was a low incidence of grades 3 and 4 adverse events. Our findings indicate that bortezomib-based combination chemotherapy can improve the prognosis of the newly diagnosed multiple myeloma patients with renal impairment and should be considered as a first-line therapy.


  • Mechanisms of Arrhythmia Recurrence After Video-Assisted Thoracoscopic Surgery for the Treatment of Atrial Fibrillation: Insights from Electrophysiological Mapping and Ablation

    by Xingpeng Liu, Jianzeng Dong, Hercules E. Mavrakis M.D., BIN Zheng, Deyong Long, Ronghui Yu, Ribo Tang, Ying Tian, Panos E. Vardas, Changsheng Ma

    Background: Video‐assisted thoracoscopic bilateral pulmonary vein (PV) isolation with left atrial appendage (LAA) excision is a novel surgical treatment for patients who have atrial fibrillation (AF) but no indication for open heart surgery. However, the electrophysiological mechanisms of the recurrent atrial tachyarrhythmias after this procedure are unknown. Methods: Eight consecutive patients with highly symptomatic atrial tachyarrhythmias after failed video‐assisted thoracoscopic surgery were included in this study. A predetermined stepwise ablation protocol, aimed at termination of the arrhythmia and isolation of all PVs, was conducted. The conduction across the remnant of the LAA was also evaluated in 4 patients. Results: Three patients had AF, which was converted into AT by complex fractionated atrial electrogram ablation in 2. Eleven sustained ATs in 7 patients were mapped during the procedure. A majority of ATs (10 of 11) were terminated by ablation before PV isolation. In total, 10 PV gaps in 7 patients were identified. All residual PV gaps were distributed exclusively in the roof or the bottom of the PV antrum. The conduction time across the remnant of the LAA was 90.7 ± 11.5 ms. One patient underwent a repeat successful ablation procedure. After a mean follow‐up of 10.1 ± 5.0 months after the last ablation procedure, 7 of 8 patients were free of clinical atrial tachyarrhythmias recurrence. Conclusion: PV gaps are present, with a characteristic distribution, in the majority of patients who fail this surgical procedure, but these gaps are not responsible for the arrhythmias identified. Instead, most are macro‐reentrant, isthmus‐dependent arrhythmias related to clamp‐associated or LAA excision‐associated scars.